Identification of anticancer drugs to radiosensitise BRAFwild-type and mutant colorectal cancer
<p><strong>Objective:</strong> Patients with BRAF-mutant colorectal cancer (CRC) have a poor prognosis. Molecular status is not currently used to select which drug to use in combination with radiotherapy. Our aim was to identify drugs that radiosensitise CRC cells with known BRAF s...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
China Anti-Cancer Association
2019
|